SEC Form 25 filed by Cutera Inc.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/22/2024 | Underperform → Mkt Perform | William Blair | |
7/27/2023 | $14.00 → $18.00 | Underweight → Neutral | Piper Sandler |
5/11/2023 | Outperform → Mkt Perform | William Blair | |
5/10/2023 | $14.00 | Underweight | Piper Sandler |
3/30/2023 | Buy → Hold | Maxim Group | |
1/31/2023 | Mkt Perform | William Blair | |
1/11/2023 | $85.00 → $33.00 | Overweight → Neutral | Cantor Fitzgerald |
12/28/2022 | $78.00 → $68.00 | Overweight | Stephens |
William Blair upgraded Cutera from Underperform to Mkt Perform
Piper Sandler upgraded Cutera from Underweight to Neutral and set a new price target of $18.00 from $14.00 previously
William Blair downgraded Cutera from Outperform to Mkt Perform
Emerges from Chapter 11 as a stronger company, well positioned for long-term growth Continuing to provide best-in-class aesthetic and dermatology solutions to customers CUTERA, INC., ("Cutera" or "the Company"), a leading provider of aesthetic and dermatology solutions, today announced that the Company has successfully completed its financial restructuring process and emerged from Chapter 11. Cutera emerges with a significantly stronger balance sheet, well positioned to drive innovation and growth. Through this process, Cutera has reduced its debt by nearly $400 million, or over 90%, and raised $65 million in new money financing from its existing lenders. "Today marks a significant mile
Cutera, Inc. ("Cutera" or the "Company") (NASDAQ:CUTR) today announced that it has formally notified The Nasdaq Stock Market LLC ("Nasdaq") of its intent to voluntarily delist its common stock from the Nasdaq Global Select Market. Cutera expects to file a Form 25 with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 20, 2025. The Company expects the delisting of the common stock to be effective on or about March 30, 2025. Following such delisting, the Company intends to file a Form 15 with the SEC to indefinitely suspend the Company's reporting obligations under the Securities Exchange Act of 1934, as amended. The s
Enters into agreement to reduce debt by nearly $400 million and raise $65 million of new money from existing lenders Implementing pre-packaged financial restructuring plan with strong support of lenders, expected to emerge expeditiously within 60 days Continues to operate as usual and provide best-in-class aesthetic and dermatology solutions to customers CUTERA, INC., ("Cutera" or "the Company"), a leading provider of aesthetic and dermatology solutions, today announced that it is initiating a restructuring transaction with the support of a group of existing lenders, representing approximately 74% of the Company's notes, to strengthen its balance sheet and position Cutera for long-term s